Germline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.
Eileen M. O’Reilly, MD
Advertisement
Articles by Eileen M. O’Reilly, MD
Advertisement
Latest Updated Articles
PALB2 Mutations Confer Susceptibility to Familial Pancreatic Cancer and May Provide a Novel Targeted Therapeutic Approach to CancerPublished: August 15th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5